{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:14:28Z","timestamp":1771017268402,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T00:00:00Z","timestamp":1395100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.tranon.2014.03.001","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T00:36:39Z","timestamp":1397781399000},"page":"349-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers"],"prefix":"10.1016","volume":"7","author":[{"given":"Julie","family":"Bauman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monte","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire F.","family":"Verschraegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Belinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Houman Fekrazad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa-Chyi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Rabinowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Ravindranathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Dennie V.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.tranon.2014.03.001_bb0005","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.1787609","article-title":"An operational definition of epigenetics","volume":"23","author":"Berger","year":"2009","journal-title":"Genes Dev"},{"issue":"Suppl 1","key":"10.1016\/j.tranon.2014.03.001_bb0010","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/ncponc0354","article-title":"DNA methylation and gene silencing in cancer","volume":"2","author":"Baylin","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"issue":"6127","key":"10.1016\/j.tranon.2014.03.001_bb0015","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.tranon.2014.03.001_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1046-2023(02)00072-5","article-title":"DNA methylation and epigenetic inheritance","volume":"27","author":"Holliday","year":"2002","journal-title":"Methods"},{"issue":"17","key":"10.1016\/j.tranon.2014.03.001_bb0025","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","article-title":"Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies","volume":"23","author":"Bhalla","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.tranon.2014.03.001_bb0030","first-page":"1596","article-title":"Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy","volume":"9","author":"Segura-Pacheco","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2014.03.001_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-4-32","article-title":"Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine","volume":"4","author":"Segura-Pacheco","year":"2006","journal-title":"J Transl Med"},{"key":"10.1016\/j.tranon.2014.03.001_bb0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2407-5-44","article-title":"A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes","volume":"5","author":"Zambrano","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2014.03.001_bb0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1475-2867-6-2","article-title":"Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines","volume":"6","author":"Chavez-Blanco","year":"2006","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0027-5107(93)90052-H","article-title":"DNA methylation and mutation","volume":"285","author":"Holliday","year":"1993","journal-title":"Mutat Res"},{"key":"10.1016\/j.tranon.2014.03.001_bb0055","first-page":"283","article-title":"Cytosine methylation and DNA repair","volume":"301","author":"Walsh","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"issue":"8","key":"10.1016\/j.tranon.2014.03.001_bb0060","first-page":"1493","article-title":"Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers","volume":"10","author":"Tornaletti","year":"1995","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.tranon.2014.03.001_bb0065","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1073\/pnas.95.12.6870","article-title":"Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma","volume":"95","author":"Herman","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2014.03.001_bb0070","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S1097-2765(03)00479-9","article-title":"Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains","volume":"12","author":"Rice","year":"2003","journal-title":"Mol Cell"},{"issue":"20","key":"10.1016\/j.tranon.2014.03.001_bb0075","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1523\/JNEUROSCI.5214-12.2013","article-title":"Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons","volume":"33","author":"Brochier","year":"2013","journal-title":"J Neurosci"},{"issue":"8","key":"10.1016\/j.tranon.2014.03.001_bb0080","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/carcin\/bgt124","article-title":"The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway","volume":"34","author":"de Conti","year":"2013","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0085","first-page":"111","article-title":"Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells","volume":"39","author":"Fortson","year":"2011","journal-title":"Int J Oncol"},{"issue":"13","key":"10.1016\/j.tranon.2014.03.001_bb0090","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1158\/0008-5472.CAN-11-0046","article-title":"Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma","volume":"71","author":"Ramsey","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-200201000-00001","article-title":"Histone deacetylase inhibitors in cancer treatment","volume":"13","author":"Vigushin","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"6711","key":"10.1016\/j.tranon.2014.03.001_bb0100","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/25166","article-title":"Regulation of activity of the transcription factor GATA-1 by acetylation","volume":"396","author":"Boyes","year":"1998","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.tranon.2014.03.001_bb0105","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.tranon.2014.03.001_bb0110","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"10.1016\/j.tranon.2014.03.001_bb0115","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/sj.onc.1203963","article-title":"Activation of the p21WAF1\/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites","volume":"19","author":"Huang","year":"2000","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/bbrc.1997.7786","article-title":"Histone deacetylase inhibitor activates the WAF1\/Cip1 gene promoter through the Sp1 sites","volume":"241","author":"Sowa","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.tranon.2014.03.001_bb0125","first-page":"1139","article-title":"p21Waf1\/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells","volume":"13","author":"Rocchi","year":"2005","journal-title":"Oncol Rep"},{"issue":"21","key":"10.1016\/j.tranon.2014.03.001_bb0130","first-page":"6068","article-title":"Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1\/Cip1 and gelsolin","volume":"60","author":"Han","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jcp.20094","article-title":"Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts","volume":"202","author":"Chen","year":"2005","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1016\/j.tranon.2014.03.001_bb0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4161\/cbt.6.2.3578","article-title":"Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells","volume":"6","author":"Valentini","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.tranon.2014.03.001_bb0145","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0014-5793(03)01186-4","article-title":"p15INK4b in HDAC inhibitor-induced growth arrest","volume":"554","author":"Hitomi","year":"2003","journal-title":"FEBS Lett"},{"issue":"3","key":"10.1016\/j.tranon.2014.03.001_bb0150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12253-012-9499-7","article-title":"SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin","volume":"18","author":"Jin","year":"2012","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.tranon.2014.03.001_bb0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-4598-5-8","article-title":"Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells","volume":"5","author":"Alao","year":"2006","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.tranon.2014.03.001_bb0160","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2184.2007.00466.x","article-title":"Inhibition of NF-\u03baB activation by the histone deacetylase inhibitor 4-Me2N-BAVAH induces an early G1 cell cycle arrest in primary hepatocytes","volume":"40","author":"Papeleu","year":"2007","journal-title":"Cell Prolif"},{"issue":"2","key":"10.1016\/j.tranon.2014.03.001_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (\u03b1\/\u03b2) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"issue":"2","key":"10.1016\/j.tranon.2014.03.001_bb0170","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejogrb.2007.02.014","article-title":"Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells","volume":"137","author":"Wu","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jnc.12292","article-title":"The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities","volume":"126","author":"Kao","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.tranon.2014.03.001_bb0180","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2121-9-66","article-title":"Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip\/WAF1 pathway","volume":"9","author":"Jung","year":"2008","journal-title":"BMC Cell Biol"},{"issue":"7","key":"10.1016\/j.tranon.2014.03.001_bb0185","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0028-3908(02)00215-0","article-title":"Regulation of Akt and glycogen synthase kinase-3\u03b2 phosphorylation by sodium valproate and lithium","volume":"43","author":"De Sarno","year":"2002","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.tranon.2014.03.001_bb0190","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1124\/mol.59.5.1269","article-title":"Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor \u03b4 by valproic acid and its teratogenic derivatives","volume":"59","author":"Werling","year":"2001","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.tranon.2014.03.001_bb0195","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1046\/j.1471-4159.1994.63062361.x","article-title":"Chronic sodium valproate selectively decreases protein kinase C \u03b1 and \u03b5 in vitro","volume":"63","author":"Chen","year":"1994","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.tranon.2014.03.001_bb0200","first-page":"248","article-title":"The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma","volume":"91","author":"Kaiser","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.tranon.2014.03.001_bb0205","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/cncr.21725","article-title":"Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells","volume":"106","author":"Morotti","year":"2006","journal-title":"Cancer"},{"issue":"8\u20139","key":"10.1016\/j.tranon.2014.03.001_bb0210","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/10408440591007403","article-title":"Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin\u2013developmental effects of valproic acid","volume":"35","author":"Wiltse","year":"2005","journal-title":"Crit Rev Toxicol"},{"issue":"12","key":"10.1016\/j.tranon.2014.03.001_bb0215","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1535-7163.MCT-05-0184","article-title":"Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC","volume":"4","author":"Li","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.tranon.2014.03.001_bb0220","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.surg.2005.09.019","article-title":"Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells","volume":"138","author":"Shen","year":"2005","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0225","first-page":"227","article-title":"Histone deacetylase inhibition by valproic acid down-regulates c-FLIP\/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy","volume":"15","author":"Schuchmann","year":"2006","journal-title":"Oncol Rep"},{"issue":"1","key":"10.1016\/j.tranon.2014.03.001_bb0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.21552","article-title":"The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia","volume":"106","author":"Kuendgen","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.tranon.2014.03.001_bb0235","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.21589","article-title":"Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia","volume":"104","author":"Bug","year":"2005","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.tranon.2014.03.001_bb0240","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non\u2013small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.tranon.2014.03.001_bb0245","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1158\/1078-0432.CCR-11-3049","article-title":"Defining a gene promoter methylation signature in sputum for lung cancer risk assessment","volume":"18","author":"Leng","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523314000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523314000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:29:36Z","timestamp":1761834576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523314000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1936523314000205"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2014.03.001","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2014.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Neoplasia Press, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}